Roche has appointed Brad Moore as president and CEO of Roche Diagnostics North America, effective January 1, 2023. Moore currently serves as senior vice president, Core Lab and Point of Care, within Roche Diagnostics North America.
Moore will succeed and report to Matt Sause, who was recently appointed CEO of Roche Diagnostics globally, effective January 1, 2023. The position will continue to be based at Roche Diagnostics’ North American headquarters in Indianapolis.
“Brad has a proven reputation for delivering outstanding results and is a highly effective leader,” says Matt Sause, current president and CEO of Roche Diagnostics North America and incumbent CEO of Roche Diagnostics. “I’m confident his experience will be a tremendous asset for the North America team, our customers and our patients.”
Moore joined Roche in October 2016 as head of North America Diabetes Care, leading commercial operations for the U.S. and Canada. In 2019, the role expanded to include the broader scope of Europe and North American commercial operations in mature markets in Europe, the U.S., Canada, Australia, and New Zealand within Roche Diabetes Care. In 2020, Moore assumed his current position, leading the newly-created Core Lab and Point of Care commercial business unit.
Founded in 1896 in Basel, Switzerland, as an early industrial manufacturer of branded medicines, Roche has grown into a worldwide biotechnology company and a global leader in in-vitro diagnostics. The company says it pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. The company says that it is a pioneer in personalized healthcare and wants to further transform how healthcare is delivered to have an even greater impact.
